Item 4, purpose of the transaction:This Amendment No. 6 to Schedule 13D (this "Amendment No. 6") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 6, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 6 shall have the meanings set forth in the Schedule 13D.Read the filing
Amneal Pharmaceuticals, Inc. AMRX
Institutional owners are on their way
13F data can be up to 45 days oldWe read every 13F filing after each quarter ends. The owners of AMRX show here after the next update.
Institutional ownership
Institutional owners
Institutional owners are on their wayWe read every 13F filing after each quarter ends. The owners of AMRX show here after the next update.
Funds that hold AMRX
Mutual funds and ETFs, each from its own latest portfolio report. Funds report on their own quarter ends.
Fund holdings are on their wayWe read the funds' N-PORT reports after each quarter. The funds that hold AMRX show here after the next update.
Superinvestors holding AMRX
The investors followed on Tickdelta, from their latest 13F.
None of the followed investors held AMRX in their latest 13F.
13D filings: owners who may push for change
Owners of more than 5%
Item 4, purpose of the transaction:This Amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 7, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 7 shall have the meanings set forth in the Schedule 13D.Read the filing
Item 4, purpose of the transaction:This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D.Read the filing
Item 4, purpose of the transaction:This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the New Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D. Between November 14, 2024 and December 31, 2025, trusts controlled by the Reporting Person sold 6,924,729 shares of Class A Common Stock in open market transactions at prices per share between $7.74 and $12.42.Read the filing
Sources
SEC's Form 13F data sets, each quarter; Form N-PORT data sets for the funds; Schedule 13D filings.
Also
Investors: the portfolios of the superinvestors followed here. Insider trades: what the company's own people bought and sold.